In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 327-330

  Arikan, S ^a   Lozano Chiu, M ^a   Paetznick, V ^a   Rex, J H ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; DRUG SENSITIVITY; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS; FUSARIUM; MICROBIAL SENSITIVITY TESTS; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC;

EID: 0035162902     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.327-330.2001     Document Type: Article

References (26)

1. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
2. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
3. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
4. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
5. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
6. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
7. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
8. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
9. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp.
10. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
11. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
12. Treatment of murine disseminated candidiasis with L-743, 872
13. Evaluation of endpoints for antifungal susceptibility determinations with LY303366
14. Growth medium effect on the antifungal activity of LY 303366
15. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
16. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase
17. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates
18. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: Influence of assay conditions
19. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
20. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents
21. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
22. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates
23. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
24. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
25. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species